AIDOT, a South Korean AI-driven healthcare innovation company, showcased its flagship solutions, Cerviray AI (cervical cancer diagnostic AI) and URO dot AI (urinary stone detection AI), at MEDICA 2025, the world’s largest medical device exhibition held in Düsseldorf, Germany, highlighting its growing presence in the global healthcare market.
MEDICA 2025 brought together more than 4,500 healthcare companies from over 70 countries, serving as a premier global stage for introducing innovative medical technologies and products.
Cerviray AI, already deployed in over 400 hospitals in South Korea and more than 10 countries worldwide, is the only domestic solution capable of precisely marking lesion locations and classifying four stages of cervical lesions by severity. Visitors at the exhibition praised its fast examination speed, intuitive interface, and infrastructure-friendly design, making it suitable for use even in developing countries.
Experts also noted its utility alongside HPV testing in advanced healthcare settings and highlighted that AI-based lesion mapping can significantly assist in pre-biopsy planning. Asian and Latin American buyers showed strong interest in Cerviray AI’s low-cost, high-efficiency screening model, leading to active on-site consultations.
Meanwhile, URO dot AI, the world’s first AI solution for automatically detecting and quantifying urinary stones from CT images, was also featured. It offers unique functionalities such as precise stone location identification, automated measurement of size and count, and reduced analysis time for clinicians. Live demonstrations of URO dot AI’s imaging analysis and user interface attracted inquiries from radiologists and medical device companies across Europe and the Middle East.
These responses reflect AIDOT’s competitive advantage: integrated medical devices, proprietary AI algorithms, and optimized design for low-resource environments, validated through continuous collaboration with leading domestic university hospitals.
AIDOT CEO Jaehun Jung stated, “Cerviray AI and URO dot AI deliver both practicality and accuracy required in real clinical settings. MEDICA marks a pivotal moment to accelerate our global expansion. Large-scale projects are already underway in Vietnam, Indonesia, and Latin America, and we aim to establish new references in Europe and the Middle East from this exhibition.”
Recognized as realistic, problem-solving AI solutions for global medical practice, Cerviray AI and URO dot AI are expected to further strengthen AIDOT’s international presence following MEDICA 2025.
Korea Economic TV / November 19, 2025 / Deputy Editor Jaejun Yang
